By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

Key Statistics

Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO


Company News
Juno (JUNO) To Report First Quarter 2016 Financial Results On Monday, May 9 5/3/2016 10:56:12 AM
Juno (JUNO), Five Prime (FPRX) are Quiet Winners at AACR 4/21/2016 6:16:52 AM
Juno (JUNO) Unveils Promising Early Data on Two CAR T Cell Product Candidates 4/21/2016 6:11:26 AM
Juno (JUNO) Announces Data Presentations At The AACR Annual Meeting 4/14/2016 11:00:33 AM
Week In Review: WuXi AppTec And Juno (JUNO) Form China Immuno-Oncology JV 4/11/2016 9:52:49 AM
Celgene (CELG) And Juno (JUNO) Announce Celgene Exercised Option To Develop And Commercialize CD19-Directed Product Candidates 4/11/2016 8:35:10 AM
Juno (JUNO) Goes Global With Launch of New China-Based JW Biotechnology (Shanghai) Co. 4/8/2016 7:04:55 AM
Booming Juno (JUNO) May Leave Washington if Policy Makers Continue to Ignore Biotech Incentives 4/4/2016 7:54:47 AM
Inside the $50 Billion Biotech Sugar Daddy that Invested in Startups Like Denali, Juno (JUNO) 3/3/2016 6:12:41 AM
Juno (JUNO) To Present At March 2016 Investor Conferences 3/2/2016 11:09:01 AM